TickerTalks
Browse all tickers →
TickerTalks›$VKTX
VKVKTX

Viking Therapeutics, Inc.

$VKTX·$3.7B·Biotechnology·Healthcare
$32.16-5.0%YTD-7.3%1Y+16.6%
Mentions · last 7 days
2026-08-19: 60 posts2026-08-20: 42 posts2026-08-21: 33 posts2026-08-22: 12 posts2026-08-23: 18 posts215-5%
Price updated 11h ago·X counts updated 5d ago
VKVKTX
$VKTXViking Therapeutics, Inc.
$32.16-5.02%215 posts-5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $VKTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

The Q3 SC maintenance data is the last big 2026 catalyst — Viking has $500M cash but insiders are quietly cashing out ahead of it.

Viking Therapeutics is a mid-cap biotech running VK2735 (dual GIP/GLP-1 agonist) through Phase 3 in obesity, plus VK2809 (thyroid-beta) in MASH. The equity has spent 2026 in a range as the market waits on the Q3 subcutaneous maintenance dosing readout — the last major 2026 catalyst before a potential Phase 3 primary readout in 2027.

Where the tension sits:

  • The pipeline breadth is real: five realistic dosing options for VK2735 (SC + oral formulations), and Piper Sandler's $71 price target is anchored on the Q3 SC maintenance data being 'underappreciated.' OBESITY Week on October 19 is the natural venue for the next scientific update.
  • The balance sheet supports one shot on goal: $502M cash gives Viking ~2 years of runway even at the current burn — a comfortable position for a pre-revenue biotech, and it means the S-3ASR $500M ATM shelf filed 7/30 isn't pressed on capital.
  • The counterweight is a fresh insider sell cluster: CEO Brian Lian sold ~$4.9M on 7/29 at $33.32, plus officers Marianna Mancini ($610K) and Greg Zante ($710K) selling the same day — that's the largest concentrated insider distribution in the recent past, and it lands right before the Q3 data window.

The path forward is the Q3 SC maintenance data readout (currently undated) plus the Q3 earnings on October 28 — a positive readout confirming durability restarts the tape upward. What breaks it: a mixed or below-expectation SC data plus continued insider distribution.

Agrees with X sentimentThe X bullish framing on Piper's $71 PT, the SC maintenance data as 'underappreciated', and OBESITY Week Oct 19 is directionally right — those are the real catalysts. But the CEO's $4.9M sale on 7/29 plus the two officer sales the same day is what the sample doesn't price, and it's the single most important signal to weigh against 'comeback story post-P3.'

What to watch: Q3 SC maintenance data readout (undated) plus October 28 Q3 earnings. A positive readout confirming durability restarts the tape upward; a mixed data readout combined with additional CEO-sized selling is what breaks the coil.

On the calendar: 2026-10-28 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment27 posts analyzed · as of 2026-08-28

Viking Therapeutics posts are decisively bullish ahead of 2H Sept-Oct VK2735 Phase 3 SC maintenance data. Bulls cite CEO Brian Lian's confident 'best in class' framing, Piper Sandler PT $71, and MRNA-type short-covering explosion expected. Bulls target 18%+ 21-week weight loss as a rerating catalyst, with $VKTX up 3x pre-data. Bears cite heavy short interest (Jane Street). Tone dominates bullish.

Read the AI verdict + X sentiment for $VKTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VKTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $VKTX

Partial — Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-100%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-71.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.10$-1.23+10.6%
Q1 2026Apr 29, 2026$-1.37$-1.01-35.6%
Q4 2025Feb 11, 2026$-1.38$-0.89-55.1%
Q3 2025Oct 22, 2025$-0.81$-0.70-15.7%
Next earningsWed, Oct 28·consensus EPS $-1.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.37$-114.0M
Q4 FY25$0———$-1.38$-85.3M
Q3 FY25$0———$-0.81$-94.0M
Q2 FY25$0———$-0.58$-47.1M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.2M$7.2M – $7.2M-$4.75-$5.78 – -$3.859
FY27$7.3M$7.3M – $7.3M-$4.77-$6.82 – -$2.3610
FY28$161.5M$161.5M – $161.5M-$3.91-$6.76 – -$0.2616
FY29$474.5M$474.5M – $474.5M-$1.73-$1.73 – -$1.7315
FY30$1.2B$1.2B – $1.2B$2.16$2.16 – $2.1615

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.46%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-4.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 113.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.695-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 29Brian LianCEO148.5K sh$4.9MSellJul 29Greg ZanteCFO21.2K sh$710KSellJul 29Marianna ManciniCOO18.2K sh$610KBuyMar 10Aubuchon Neil WilliamChief Commercial Officer4.5K sh$150K
+ 5 other (5 awards) in window

See when $VKTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 73
AI summary

A reporting person filed an initial Form 3 at Viking Therapeutics (VKTX), disclosing no securities are beneficially owned — no common stock, options, or derivative securities. This is a routine initial Section 16 reporting obligation for a new insider or 10%-plus holder.

S-3ASRAuto-shelf registrationJul 30S-3ASR
AI summary

Viking Therapeutics, Inc. (VKTX) filed an automatic shelf registration (S-3ASR) as a large accelerated filer, registering securities for offerings from time to time, including a sales agreement prospectus for an ATM facility of up to $500 million of common stock through Stifel, Piper Sandler, Cantor Fitzgerald, and Oppenheimer. The shelf registration enables both primary issuances and selling shareholder resales. This is a standard capital markets flexibility tool; the $500M ATM represents potential dilution for Viking shareholders but is not an immediate offering.

3New insider — initial holdingsJun 33
AI summary

A new insider filed a Form 3 with the SEC, disclosing initial beneficial ownership of VKTX securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at VKTX.

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Viking Therapeutics held its 2026 Annual Meeting on May 19, 2026 with 80.1M of 115.9M shares (69.1%) represented. Elected Class II directors for terms through 2029: J. Matthew Singleton (28.6M for, 14.6M withheld) and S. Kathryn Rouan, Ph.D. (22.0M for, 21.3M withheld—notably contested). Ratified CBIZ CPAs P.C. as auditor (78.4M for, 1.2M against). Rouan's high withhold vote (~49% of non-broker votes) is the notable outcome and may reflect institutional governance concerns.

+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?zacks.com·20h agoViking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?fool.com·2d agoLLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?zacks.com·12d ago2 GLP-1 Stocks That Could Double Your Money by 2031fool.com·13d agoBetter GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?fool.com·21d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport